Latest Product Launches News

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Activeport’s Global Edge platform has secured contracts with Spark and ViewQwest, setting the stage for a significant uplift in recurring revenue and international expansion.

Datagate Innovation Limited reports steady 23% ARR growth despite customer churn and pricing pressure, while targeting a US$5 million ARR milestone to enhance its valuation over the next two years.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

Atomos Limited has trimmed its FY26 sales guidance to approximately $40 million due to softer end-consumer demand and delayed product shipments, while forecasting EBITDA between $2.5 million and $3.5 million supported by improved margins.

Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.

SunRice reported a 4% rise in net profit after tax for FY26 to $73.3 million, maintaining an 8% EBITDA margin despite a 2.5% revenue decline. The company declared a record fully franked dividend of 70 cents per share but expects FY27 profit to fall amid a smaller Australian rice crop.

The a2 Milk Company has announced a $300 million fully franked special dividend following regulatory clearance in China to rebrand infant formula products under its a2 label.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.